Gamunex-C: Clinical Trials

3 trials of Gamunex-C, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 recruiting, 1 terminated. 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 33Completed 1, Recruiting 1, Terminated 1

Follow Gamunex-C: new trials by email Literature Review of Gamunex-C trials Research Report on Gamunex-C

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Gamunex-C, Xembify - CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
Phase 3RecruitingGrifols Therapeutics LLC402026-04-022026-11-10
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency
Gamunex-C, IVIG-PEG - Primary Immunodeficiency
Phase 3CompletedGrifols Therapeutics LLC332020-09-022023-06-05
IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy
Intravenous Immunoglobulin, Placebos, Normal Saline - Autoimmune Epilepsy
Phase 3TerminatedMayo Clinic172016-02-012019-12-30

Conditions studied

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (1)  ·  Primary Immunodeficiency Diseases (1)

Sponsors

Grifols Therapeutics LLC (2)  ·  Mayo Clinic (1)

Countries

United States (3)  ·  Czechia (1)  ·  Poland (1)  ·  Romania (1)

Top investigators

Sean Pittock, M.D. (1)